Millipore announced this week the availability of its ProSep affinity chromatography media designed to facilitate the purification of antibodies. ProSep chromatography media exhibit chemical and mechanical stability over a range of conditions, such as low pH, exposure to detergents and buffers of varying ionic strengths, and permit high flow rates with low back pressure, according to Millipore.
The ProSep media come in three forms: ProSep-vA Ultra media are designed to facilitate purification of antibodies in general; ProSep-G is recommended for purification of antibodies that do not bind efficiently to protein A, such as rat IgGs and human IgG3; ProSep-PB media is designed for the affinity chromatography of a variety of glycoproteins, nucleic acids, and other biomolcules containing 1.2 diol functionality.
Movers & Shakers
Applied Biosystems announced this week that Mark Stevenson has been appointed president of the firm's molecular biology division. He previously served as president of the firm's applied markets division. Stevenson succeeds William Murray, who has resigned due to personal reasons.
ABI also announced that Leonard Klevan has replaced Stevenson as president of the applied markets division. Klevan had joined ABI earlier this year as vice president of R&D for applied markets. Before joining ABI, he was CEO of ReliaGene Technologies. He also is a former president and CEO of MiraiBio, a subsidiary of Hitachi Software Engineering, and had managed technology acquisitions and business development at Life Technologies, which was acquired by Invitrogen in 2000.
Leroy Hood, president and co-founder of Institute for Systems Biology, and Josh LaBaer, founder and director of the Institute of Proteomics at Harvard Medical School, have joined Lumera's scientific advisory board.
Ciphergen Biosystems has appointed Kenneth Conway to its board. Conway founded Millennium Predictive Medicine and Vitivity, both of which focus on the predictive medicine arena. He holds a BS from Rutgers University and attended the Executive Program at Dartmouth College's Dartmouth Institute, Tuck School of Business Administration.
Sigma-Aldrich has named Carl Turza chief information officer, effective May 1. Turza, 47, has worked at W.W. Grainger, AlliedSignal Aerospace, and other "large and complex" organizations. He holds an MBA from the University of Illinois in Chicago and a BA in economics from the University of Illinois in Champaign.
BD Biosciences announced that it has promoted William Rhodes to the position of president, cell analysis. The unit has been restructured and Rhodes has taken on additional responsibilities including the sales and technical service organizations. Previously, Rhodes was vice president/general manager for Cell Analysis.
He holds an MS in international business from Seton Hall University and a BS from Cornell University.
Upstream Biosciences has appointed Tim Fernback as chief financial officer. Since 2002, Fernback has been an active director of the Okanagan Capital Fund, an Okanagan, Canada-based technology venture fund. He is a graduate of McMaster University, where he studied molecular biology and biochemistry, and also a graduate of the University of British Columbia, where he completed his MBA with a concentration in finance.